Mar. 2025 Fineline Deals Book
China Pharmaceutical BD Transaction Review – Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. – Fineline Deals Book Mar. 2025
According to incomplete statistics from Fineline Info & Tech, there were a total of 21 pharmaceutical BD and M&A transactions in China in Mar 2025, including 3 cross-border asset acquisitions, 7 outbound transactions, and 11 domestic transactions.
Cross-border License In
Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),… [Full Artical]
WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA… [Full Artical]
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton… [Full Artical]
Cross-border License Out
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca… [Full Artical]
Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases
China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a…[Full Artical]
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement…[Full Artical]
Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe… [Full Artical]
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s…[Full Artical]
Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone
Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration…[Full Artical]
Domestic Transactions in China
Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm… [Full Artical]
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered… [Full Artical]
Sino Biopharmaceutical Licenses Nanjing Delova’s QP001 for Mainland China Rights
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s…[Full Artical]
Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance… [Full Artical]
Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery
Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi…[Full Artical]
Convalife and XLement Launch AI-Powered Joint Lab for Drug Development Innovation
On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the… [Full Artical]
Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an…[Full Artical]
Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap… [Full Artical]
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm…[Full Artical]
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot… [Full Artical]
Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment
Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based…[Full Artical]
For more insights, follow Fineline Info & Tech